On Monday, Following U.S. Stocks were among the “Top Losers”: Civeo Corporation (NYSE:CVEO), Curis, Inc. (NASDAQ:CRIS), Revolution Lighting Technologies, Inc. (NASDAQ:RVLT), Geron Corporation (NASDAQ:GERN)

Civeo Corporation (NYSE:CVEO)

Civeo Corporation (CVEO), stated financial results for the fourth quarter and full year ended December 31, 2014.

Brief Summary:

• Fourth quarter proceed and Adjusted EBITDA, not including impairments and other items, exceeded formerly offered guidance.
• Maintaining first quarter 2015 guidance and adjusting full year guidance for weakness in Australian and Canadian dollars.
• Continue to focus on maximizing occupancy and proceeds, reducing costs and limiting capital spending.

The Corporation invested $42.9 million in capital expenditures during the fourth quarter of 2014. Capital spending during the quarter was primarily related to the Canadian business, which comprised of the initial construction of the McClelland Lake lodge, in addition to routine capital maintenance spending in Canada and Australia. The Corporation presently anticipates to spend about $75 to $85 million in capital expenditures for the full year of 2015.

As of the end of the fourth quarter, the Corporation had total liquidity of about $685.5 million, comprising $422.2 million accessible under its credit facilities and $263.3 million of cash on hand. Based on our current forecasts for 2015, we expect that we will be required to reduce our outstanding indebtedness in order to comply with the maximum leverage ratio covenant as required under our Credit Facility, particularly in the third and fourth quarters of 2015.

Civeo Corporation is a leading provider of workforce accommodations with prominent market positions in the Canadian oil sands and the Australian natural resource regions. Civeo offers comprehensive solutions for housing hundreds or thousands of workers with its long-term and temporary accommodations and provides catering, facility administration, water systems and logistics services.

Curis, Inc. (NASDAQ:CRIS)

Formerly on March 2, Curis, Inc. (CRIS), declared the closing of its formerly declared public offering of ordinary stock. Curis sold 25,090,908 shares of its ordinary stock in the offering at a price to the public of $2.75 per share, counting the exercise in full by the underwriters of their option to purchase an additional 3,272,727 shares of ordinary stock at the public offering price. Curis received net proceeds of about $64.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Cowen and Corporation, LLC and RBC Capital Markets acted as joint book-running managers. Robert W. Baird & Co. Incorporated and Roth Capital Partners, LLC acted as co-lead managers for the offering.

Curis is a biotechnology corporation focused on the development and commercialization of innovative drug candidates for the treatment of human cancers.

Revolution Lighting Technologies, Inc. (NASDAQ:RVLT)

Revolution Lighting Technologies, Inc. (RVLT), declared financial results for the fourth quarter and full year ended December 31, 2014. Stated proceeds for FY 2014 were $76.8 million with $27.5 million in Q4.

According to a U.S. Department of Energy study, LED share of market is predictable to account for $72 billion of the $105 billion general lighting market by 2020. Through attainments, raised brand administration capabilities and a robust new product development pipeline, RVLT is working aggressively to capture market share in a world that is seeing rapid LED growth. RVLT introduced over 60 new products in 2014 and will continue to support its customers, and the LED market, through a robust engineered and plannedally sourced new product development process.

In 2014, the Corporation started the integration of its indoor and outdoor products under the RVLT brand. Seesmart offers an extensive line of high-quality interior and exterior LED lamps and fixtures. Relume offers highly efficient outdoor LED products. Integrating these two powerful brands into RVLT not only expands the Corporation’s focus on the commercial, industrial, hospitality, healthcare, education, and government verticals, but also allows it to become one of the nation’s fastest-growing LED lighting brands.

Business Highlights for Full Year 2014:

• December 29th: The Corporation reached a planned distribution partnership with Fastenal Corporation. Fastenal is one of the largest MRO (Maintenance, Repair, Operations) suppliers.
• December 18th: Declared that its Seesmart™ brand LED household and PAR lamps are now accessible on Staples.com.
• December 1st: The Corporation accomplished an offering of 8 million shares of its ordinary stock.
• December 1st: The Corporation converted all outstanding preferred stock and unpaid dividends into ordinary stock.
• October 23rd: Declared the retrofit installation of 40,000 LED tube lights in New Brunswick Public Schools.
• October 22nd: The Corporation filed a universal shelf registration statement (not to exceed $50 million) on Form S-3 with SEC.
• September 26th: The Corporation accomplished the retrofit of the Connecticut Convention Center, located in Hartford, Connecticut; the largest energy reduction project in the state.
• August 20th: The Corporation reached a three year loan and security contract with Bank of America. The contract allows the Corporation to borrow up to $25 million on a revolving basis.
• June 11th: Declared that SL Green Realty Corp., New York City’s largest commercial property owner, selected Revolution Lighting’s Seesmart™ brand LED tube lamps for an LED retrofit at nine commercial office properties.
• April 17th: The Corporation accomplished the attainment of Value Lighting a supplier of lighting solutions to the multifamily and apartment housing market.
• April 3rd: Declared the launch of Seesmart brand Generation 3 (G3) LED T8 tube lamps featuring an innovative all-plastic construction with a thermoplastic heat sink for cool, efficient operation.

Revolution Lighting Technologies, Inc., together with its auxiliaries, designs, manufactures, markets, and sells light emitting diode (LED) replacement lamps and fixtures; and LED-based signage, channel-letter, and contour lighting products.

Geron Corporation (NASDAQ:GERN)

Formerly on March 3, Geron Corporation (GERN), stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.

Fourth Quarter 2014 Results:

Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, contrast to $9.3 million, or $0.07 per share, for the comparable 2013 period. Proceeds for the fourth quarter of 2014 were $178,000 contrast to $225,000 for the comparable 2013 period. The corporation ended 2014 with $170.6 million in cash and investments, which comprised of receipt of an upfront payment of $35.0 million for the license rights granted by the corporation to Janssen Biotech, Inc. (“Janssen”) under the exclusive partnership and license contract (the “Partnership Contract”) reached between the parties in November 2014, which has been recorded as deferred proceed as of December 31, 2014.

Total operating expenses for the fourth quarter of 2014 were $9.2 million contrast to $9.5 million for the comparable 2013 period. Research and development expenses for the fourth quarter of 2014 were $4.4 million contrast to $5.1 million for the comparable 2013 period. General and administrative expenses for the fourth quarter of 2014 were $4.8 million contrast to $4.0 million for the comparable 2013 period. Operating expenses for the 2013 fourth quarter also comprised of restructuring charges of $430,000 in connection with the corporation`s decisions to discontinue its discovery research programs and close its research laboratory facility in 2013.

The decrease in research and development expenses for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects lower manufacturing costs for imetelstat drug product and reduced clinical trial expenses for the imetelstat trials in hematologic myeloid malignancies. The raise in general and administrative expenses for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects the net result of higher non-cash stock-based compensation expense, raised legal fees for the purported lawsuits filed against the corporation and transaction costs associated with the Partnership Contract with Janssen, partially offset by transaction costs associated with the closing of the stem cell divestiture transaction in October 2013.

Interest and other revenue for the fourth quarter of 2014 was $100,000 contrast to $115,000 for the comparable 2013 period. The decrease in interest and other revenue for the fourth quarter of 2014, contrast to the same period in 2013, primarily reflects the net result of a gain on the sale of excess laboratory equipment in connection with the closure of the corporation`s research laboratory facility in 2013, partially offset by higher interest revenue due to raised cash and investment balances with the receipt of $96.8 million in net cash proceeds from the underwritten public offering accomplished in February 2014.

Geron Corporation, a clinical stage biopharmaceutical corporation, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The corporation was founded in 1990 and is based in Menlo Park, California.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.